Michael Triplett

Dr. Michael Triplett is a serial life sciences entrepreneur focused on disruptive biotechnology innovations, co-founding and serving on the board of Clarametyx Bio, Armatus Bio, and Neucore Bio. He also serves the boards of Andelyn Biosciences, the NeuroTech Institute, the Ohio Life Sciences Association (chair), and InnovateOhio. He previously founded Myonexus Therapeutics, serving as CEO until its acquisition by Sarepta Therapeutics. Dr. Triplett received his B.S. in Chemical Engineering (summa cum laude) and Ph.D. in Chemical Engineering from The Ohio State University as a United States Department of Defense National Defense Science and Engineering Graduate Fellow and University Fellow.